Immunotherapy, a form of personalized cancer treatment, currently requires a tumor sample to be removed surgically and analyzed so that the personalized treatment needed by the patient can be manufactured. However, obtaining the needed tumor sample can be challenging in many patients, such as those with tumors in hard-to-access parts of the body or those whose physical condition makes it risky to have surgery done to extract a sample.
This limitation is significant because personalized immunotherapies must be tailored to the unique neoantigens expressed by a patient's tumor. Without a sufficient tumor sample, the development of these therapies can be delayed or rendered impossible. A blood-based approach could potentially overcome this barrier by using a simple blood draw to identify cancer-specific proteins and T-cell activation. If additional clinical trials confirm the efficacy of the blood-based approach to obtaining data on cancer neoantigens and specific T-cell activation, the method could potentially reduce the time that is required to manufacture immunotherapies developed by entities like Calidi Biotherapeutics Inc. (NYSE American: CLDI).
The potential impact on the immunotherapy industry is substantial. A blood-based method could expand access to personalized treatments for patients who cannot undergo surgery, accelerate the manufacturing timeline, and reduce costs associated with surgical procedures. However, the approach is still experimental and requires validation in larger clinical trials. Until then, surgical tumor sampling remains the standard. Read More>>
For ongoing coverage of biotechnology and biomedical developments, BioMedWire provides specialized communications focused on the latest advancements in these sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries. The platform also offers editorial syndication to 5,000+ outlets and social media distribution via IBN to millions of social media followers.
As the biotechnology sector continues to evolve, the development of blood-based biomarkers for immunotherapy could represent a significant step toward more accessible and efficient personalized cancer treatment. The next phase of clinical trials will be crucial in determining whether this approach can become a viable alternative to surgical tumor sampling.
